Page 50 - 《中国药科大学学报》2025年第5期

582 学报 Journal of China Pharmaceutical University 2025, 56(5): 572 − 582 第 56 卷

+
tryptophan metabolism to stimulate CD8 T-cell function in col-
References
orectal cancer[J]. Cancer Res, 2023, 83(14): 2358-2371.
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics [17] Wang Y, Xu WB, Yan ZX, et al. Metformin induces autophagy
2022: GLOBOCAN estimates of incidence and mortality world- and G0/G1 phase cell cycle arrest in myeloma by targeting the
wide for 36 cancers in 185 countries[J]. CA Cancer J Clin, AMPK/mTORC1 and mTORC2 pathways[J]. J Exp Clin Can-
2024, 74(3): 229-263. cer Res, 2018, 37(1): 63.
[2] Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcino- [18] Liu FF, Chen JY, Li K, et al. Ubiquitination and deubiquitina-
ma[J]. Lancet, 2022, 400(10360): 1345-1362. tion in cancer: from mechanisms to novel therapeutic approach-
[3] Liu H, Yao ZQ, Sun MN, et al. Inhibition of AKR1Cs by liquir- es[J]. Mol Cancer, 2024, 23(1): 148.
itigenin and the structural basis[J]. Chem Biol Interact, 2023, [19] Vargas JNS, Hamasaki M, Kawabata T, et al. The mechanisms
385: 110654. and roles of selective autophagy in mammals[J]. Nat Rev Mol
[4] Kljun J, Pavlič R, Hafner E, et al. Ruthenium complexes show Cell Biol, 2023, 24(3): 167-185.
potent inhibition of AKR1C1, AKR1C2, and AKR1C3 en- [20] Komatsu M, Kageyama S, Ichimura Y. p62/SQSTM1/A170:
zymes and anti-proliferative action against chemoresistant ovar- physiology and pathology[J]. Pharmacol Res, 2012, 66(6): 457-
ian cancer cell line[J]. Front Pharmacol, 2022, 13: 920379. 462.
[5] Yepuru M, Wu ZZ, Kulkarni A, et al. Steroidogenic enzyme [21] Pernicova I, Korbonits M. Metformin: mode of action and clini-
AKR1C3 is a novel androgen receptor-selective coactivator that cal implications for diabetes and cancer[J]. Nat Rev Endocrinol,
promotes prostate cancer growth[J]. Clin Cancer Res, 2013, 2014, 10(3): 143-156.
19(20): 5613-5625. [22] Zhang CS, Li MQ, Ma T, et al. Metformin activates AMPK
[6] Chu XL, He SY, Liu Y, et al. Overview of human 20 alpha-hy- through the lysosomal pathway[J]. Cell Metab, 2016, 24(4):
droxysteroid dehydrogenase (AKR1C1): functions, regulation, 521-522.
and structural insights of inhibitors[J]. Chem Biol Interact, [23] Endo S, Oguri H, Segawa J, et al. Development of novel
2022, 351: 109746. AKR1C3 inhibitors as new potential treatment for castration-re-
[7] Nakarai C, Osawa K, Akiyama M, et al. Expression of sistant prostate cancer[J]. J Med Chem, 2020, 63(18): 10396-
AKR1C3 and CNN 3 as markers for detection of lymph node 10411.
metastases in colorectal cancer[J]. Clin Exp Med, 2015, 15(3): [24] He SY, Liu Y, Chu XL, et al. Discovery of novel aldo-keto re-
333-341. ductase 1C3 inhibitors as chemotherapeutic potentiators for can-
[8] Wang KZ, Yang WW, Xu SY, et al. Effects and mechanisms of cer drug resistance[J]. ACS Med Chem Lett, 2022, 13(8): 1286-
AKR1C3 inducing doxorubicin resis- tance in breast cancer[J]. 1294.
J China Pharm Univ(中国药科大学学报), 2021, 52(3): 352- [25] Wu CQ, Dai CL, Li XY, et al. AKR1C3-dependent lipid droplet
360. formation confers hepatocellular carcinoma cell adaptability to
[9] Zhou QQ, Tian W, Jiang ZY, et al. A positive feedback loop of targeted therapy[J]. Theranostics, 2022, 12(18): 7681-7698.
AKR1C3-mediated activation of NF-κB and STAT3 facilitates [26] Liu JX, Wu YY, Meng S, et al. Selective autophagy in cancer:
proliferation and metastasis in hepatocellular carcinoma[J]. mechanisms, therapeutic implications, and future
Cancer Res, 2021, 81(5): 1361-1374. perspectives[J]. Mol Cancer, 2024, 23(1): 22.
[10] Pan D, Yang WW, Zeng Y, et al. AKR1C3 regulated by [27] Ma ZC, Bai J, Jiang CL, et al. Tegument protein UL21 of alpha-
NRF2/MAFG complex promotes proliferation via stabilizing herpesvirus inhibits the innate immunity by triggering CGAS
PARP1 in hepatocellular carcinoma[J]. Oncogene, 2022, degradation through TOLLIP-mediated selective autophagy[J].
41(31): 3846-3858. Autophagy, 2023, 19(5): 1512-1532.
[11] Li X, Yang KB, Chen W, et al. CUL3 (cullin 3)-mediated ubiq- [28] Rasmussen NL, Zhou JW, Olsvik H, et al. The inflammation re-
uitination and degradation of BECN1 (beclin 1) inhibit au- pressor TNIP1/ABIN-1 is degraded by autophagy following
tophagy and promote tumor progression[J]. Autophagy, 2021, TBK1 phosphorylation of its LIR[J]. Autophagy, 2023, 19(10):
17(12): 4323-4340. 2819-2820.
[12] Satyavarapu EM, Nath S, Mandal C. Desialylation of Atg5 by [29] Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphoryla-
sialidase (Neu2) enhances autophagosome formation to induce tion of ULK1 (hATG1) by AMP-activated protein kinase con-
anchorage-dependent cell death in ovarian cancer cells[J]. Cell nects energy sensing to mitophagy[J]. Science, 2011,
Death Discov, 2021, 7(1): 26. 331(6016): 456-461.
[13] Liu D, Li MQ, Zhao ZY, et al. Targeting the TRIM14/USP14 [30] Sakamoto K, Jessen N. PEN2: Metformin’s new partner at lyso-
axis enhances immunotherapy efficacy by inducing autophagic some[J]. Cell Res, 2022, 32(6): 507-508.
degradation of PD-L1[J]. Cancer Res, 2024, 84(17): 2806-2819. [31] White J, Choi YB, Zhang JW, et al. Phosphorylation of the se-
[14] Yu OHY, Suissa S. Metformin and cancer: solutions to a real- lective autophagy receptor TAX1BP1 by TBK1 and IKBKE/IK-
world evidence failure[J]. Diabetes Care, 2023, 46(5): 904-912. Ki promotes ATG8-family protein-dependent clearance of
[15] Papachristodoulou A, Heidegger I, Virk RK, et al. Metformin MAVS aggregates[J]. Autophagy, 2025, 21(1): 160-177.
overcomes the consequences of NKX3.1 loss to suppress [32] Yamamoto K, Venida A, Yano J, et al. Autophagy promotes
prostate cancer progression[J]. Eur Urol, 2024, 85(4): 361-372. immune evasion of pancreatic cancer by degrading MHC-I[J].
[16] Huang XW, Sun TT, Wang JL, et al. Metformin reprograms Nature, 2020, 581(7806): 100-105.